Home Cart Sign in  
Chemical Structure| 747412-49-3 Chemical Structure| 747412-49-3
Chemical Structure| 747412-49-3

Luminespib

CAS No.: 747412-49-3

Luminespib (VER-52296) is a potent HSP90 inhibitor with IC50 values of 7.8 nM for HSP90α and 21 nM for HSP90β.

Synonyms: NVP-AUY922; AUY922; VER-52296

4.5 *For Research Use Only !

Cat. No.: A180168 Purity: 98%

Change View

Size Price

USA Stock *0-1 Day

Global Stock *5-7 Days

In Stock
1mg ł§Ê¶ÊÊ Inquiry Inquiry
5mg łÍî¶ÊÊ Inquiry Inquiry
10mg łòó¶ÊÊ Inquiry Inquiry
25mg łÇ§ò¶ÊÊ Inquiry Inquiry
50mg łËËď¶ÊÊ Inquiry Inquiry
100mg ł§ÍʶÊÊ Inquiry Inquiry
250mg łòÿǶÊÊ Inquiry Inquiry
1g łÇ§ďǶÊÊ Inquiry Inquiry

  • 1mg

    ł§Ê¶ÊÊ

  • 5mg

    łÍî¶ÊÊ

  • 10mg

    łòó¶ÊÊ

  • 25mg

    łÇ§ò¶ÊÊ

  • 50mg

    łËËď¶ÊÊ

  • 100mg

    ł§ÍʶÊÊ

  • 250mg

    łòÿǶÊÊ

  • 1g

    łÇ§ďǶÊÊ

In Stock

- +

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of [ Luminespib ]

CAS No. :747412-49-3
Formula : C26H31N3O5
M.W : 465.54
SMILES Code : O=C(C1=NOC(C2=CC(C(C)C)=C(O)C=C2O)=C1C3=CC=C(CN4CCOCC4)C=C3)NCC
Synonyms :
NVP-AUY922; AUY922; VER-52296
MDL No. :MFCD14635361
InChI Key :NDAZATDQFDPQBD-UHFFFAOYSA-N
Pubchem ID :135539077

Safety of [ Luminespib ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P261-P305+P351+P338

Related Pathways of [ Luminespib ]

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
WE-68 cells 10-50 nM 48 h Induced apoptosis and mitochondrial membrane potential loss PMC7981928
A673 cells 10-50 nM 48 h Induced apoptosis and mitochondrial membrane potential loss PMC7981928
human fibroblasts 200 nM 48 h Inhibiting Hsp90 activity to increase TPIE105D protein stability PMC7993632
LGSOC cells 10 nM 7 weeks To evaluate the long-term efficacy of Luminespib on LGSOC cells, the results showed that Luminespib monotherapy was effective initially, but cell viability rebounded later, while combination therapy continued to suppress cell viability. PMC10583378
LGSOC cells 10 nM 46 days To evaluate the long-term therapeutic effect of Luminespib on LGSOC cells, results showed that Luminespib significantly reduced cancer cell viability. PMC10583378
RAW-Lucia ISG cells 1 µM 24 h To assess the effect of Luminespib on type I IFN production, results showed that Luminespib significantly enhanced type I IFN production. PMC10711858
MC38 cells 0.5 µM 24 h To assess the effect of Luminespib and emricasan combination treatment on IFN-β expression, results showed that the combination treatment significantly enhanced IFN-β expression. PMC10711858

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
Mice LGSOC peritoneal metastasis model Intraperitoneal injection 5 mg/kg 3 times a week, until endpoint To evaluate the efficacy of Luminespib monotherapy and combination therapy in the LGSOC peritoneal metastasis model, the results showed that Luminespib monotherapy slowed tumor growth, but combination therapy significantly prolonged mouse survival. PMC10583378
mice LGSOC peritoneal metastasis model intraperitoneal injection 5 mg/kg 3 times a week, for 60 days To evaluate the therapeutic effect of Luminespib on the LGSOC peritoneal metastasis model, results showed that Luminespib significantly delayed tumor formation and increased animal survival. PMC10583378
C57BL/6J mice MC38 tumor model intraperitoneal injection 75 mg/kg every 2 days for a total of five times To evaluate the effect of Luminespib and emricasan combination treatment on tumor growth, results showed that the combination treatment significantly inhibited tumor growth with a tumor growth inhibition (TGI) rate of 71%. PMC10711858

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01668173 Myeloproliferative Neoplasms PHASE2 TERMINATED 2025-05-15 Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States Less <<
NCT01132625 Advanced Solid Tumors PHASE1 COMPLETED 2025-05-12 Novartis Investigative Site, K... More >>ashiwa, Chiba, 277-8577, Japan|Novartis Investigative Site, Sunto-gun, Shizuoka, 411-8777, Japan Less <<
NCT01922583 Non-small Cell Lung Cancer (NS... More >>CLC) Less << PHASE2 COMPLETED 2025-02-17 National Cheng Kung University... More >> Hospital, Tainan, 70403, Taiwan|Department of Oncology, National Taiwan University Hospital, Taipei, 100, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan Less <<
NCT01124864 Non-small-cell Lung Cancer PHASE2 COMPLETED 2025-08-14 University of California at Lo... More >>s Angeles UCLA - Santa Monica, Los Angeles, California, 90095, United States|Maryland Oncology Hematology, P.A. Dept. of Assoc. Onc/Hem, Rockville, Maryland, 20850, United States|Dana Farber Cancer Institute DFCI, Boston, Massachusetts, 02215, United States|St. Luke's Hospital and Health Network St Luke's, Bethlehem, Pennsylvania, United States|Novartis Investigative Site, Edmonton, Alberta, T6G 1Z2, Canada|Novartis Investigative Site, Montreal, Quebec, H3T 1E2, Canada|Novartis Investigative Site, Creteil, 94000, France|Novartis Investigative Site, Marseille cedex 20, 13915, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Berlin, 13125, Germany|Novartis Investigative Site, Oldenburg, 26121, Germany|Novartis Investigative Site, Seoul, Korea, 05505, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, 06351, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, 110 744, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, 137-701, Korea, Republic of|Novartis Investigative Site, Amsterdam, 1081 HV, Netherlands|Novartis Investigative Site, Groningen, 9713 GZ, Netherlands|Novartis Investigative Site, Oslo, NO-0379, Norway|Novartis Investigative Site, Singapore, 119228, Singapore|Novartis Investigative Site, Badalona, Catalunya, 08916, Spain|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Izmir, 35040, Turkey Less <<
NCT01389583 Gastrointestinal Stromal Tumor PHASE2 UNKNOWN 2025-10-19 National Health Research of In... More >>stitutes, Taiwan Cooperative Oncology Group, Tainan, Taiwan Less <<
NCT01404650 Gastrointestinal Stromal Tumor PHASE2 COMPLETED 2025-02-15 Yale School of Medicine, New H... More >>aven, Connecticut, 06520, United States|Florida Cancer Specialists-South, Ft. Myers, Florida, 33916, United States|Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States|Woodlands Medical Center, Pensacola, Florida, 32503, United States|Florida Cancer Specialists-North, St. Petersburg, Florida, 33705, United States|Research Medical Center, Kansas City, Missouri, 64132, United States|Nebraska Methodist Hospital, Omaha, Nebraska, 68114, United States|Tennessee Oncology, Nashville, Tennessee, 37203, United States Less <<
NCT01361945 Breast Cancer|Metastatic Breas... More >>t Cancer|HER-2 Positive Breast Cancer|ER Positive Breast Cancer Less << PHASE1|PHASE2 WITHDRAWN 2025-08-12 -
NCT01485536 Lymphoma PHASE2 TERMINATED 2025-11-15 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01484860 Adenocarcinoma of the Pancreas... More >>|Metastatic Disease Less << PHASE2 TERMINATED 2025-08-13 Princess Margaret Hospital, To... More >>ronto, Ontario, M5G 2M9, Canada Less <<
NCT01752400 Non Small Cell Lung Cancer PHASE2 COMPLETED 2025-11-17 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT01854034 Non Small Cell Lung Cancer PHASE2 COMPLETED 2025-03-17 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.21mL

10.74mL

2.15mL

1.07mL

21.48mL

4.30mL

2.15mL

References

 

Historical Records

Categories